FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically, to a peptide binding to annexin A1, and can be used in medicine.
EFFECT: produced peptide with the amino acid sequence C[D]T[D]I[D]T[D]W[D]P[D]T[D]M[D], wherein amino acids are presented in a D form, can be used to effectively treat a malignant tumour.
1 cl, 12 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNITY INDUCER | 2016 |
|
RU2758112C2 |
| ANTIBODY AGAINST MALIGNANT CELL, ANTI-CANCER DRUG AND METHOD FOR TESTING MALIGNANT NEOPLASM | 2015 |
|
RU2753512C2 |
| VACCINE COMPOSITION FOR TREATMENT OF CANCER | 2018 |
|
RU2782261C2 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| MYL9 ANTIBODY | 2017 |
|
RU2741802C2 |
| ADENOVIRUSES AND METHODS FOR ADENOVIRUS APPLICATION | 2019 |
|
RU2782528C1 |
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| PEPTIDE DERIVED FROM FOXM1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2738418C2 |
| IL-10/FC FUSION PROTEINS SUITABLE AS IMMUNOTHERAPY ENHANCERS | 2020 |
|
RU2825306C1 |
| FUSION CONSTRUCTION CONTAINING CELL PENETRATING PEPTIDE, POLYEPITOPE AND TLR PEPTIDE AGONIST, INTENDED FOR TREATMENT OF CANCER | 2017 |
|
RU2807135C2 |
